# Immunovia > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/immunovia). ## Overview Immunovia AB is a diagnostic company focused on increasing survival rates for patients with pancreatic cancer through early detection. The company specializes in developing and commercializing blood-based tests that detect proteins and antibodies indicative of pancreatic cancer in high-risk individuals. Immunovia collaborates with healthcare providers, leading experts, and patient advocacy groups to make its tests widely available. The company's shares are listed on Nasdaq Stockholm, and it is headquartered in Lund, Sweden. ## Products & services • PancreaSure test for early detection of pancreatic cancer • Blood-based diagnostic tests • Clinical data and testing services • Strategic partnerships for test commercialization - **Diagnostic Tests** (70%) — Blood-based tests for detecting pancreatic cancer - **Clinical Data Services** (20%) — Services providing clinical data and testing results - **Strategic Partnerships** (10%) — Collaborations for commercialization and distribution - PancreaSure test for early detection of pancreatic cancer - Blood-based diagnostic tests - Clinical data and testing services - Strategic partnerships for test commercialization ## Customers Immunovia's primary customers are healthcare providers and medical centers that focus on high-risk pancreatic cancer surveillance. These customers integrate Immunovia's PancreaSure test into their surveillance protocols to enhance early detection capabilities. The company also targets strategic partners in the diagnostics industry to expand its commercial reach and accelerate market penetration. Additionally, Immunovia engages with patient advocacy groups to raise awareness and promote the adoption of its testing solutions. - **Healthcare Providers** (primary) — Purchase PancreaSure for early detection in high-risk patients - **Medical Centers** (primary) — Integrate tests into surveillance protocols - **Diagnostics Companies** (secondary) — Collaborate for commercialization and distribution - **Patient Advocacy Groups** (emerging) — Support awareness and adoption of testing solutions - Healthcare providers integrating PancreaSure for early cancer detection - Medical centers with high-risk pancreatic cancer surveillance programs - Strategic partners in the diagnostics industry for commercialization - Patient advocacy groups promoting test adoption ## Geography Immunovia is headquartered in Lund, Sweden, and its primary market is the United States, which is the largest market for pancreatic cancer detection. The company estimates that 1.8 million individuals in the USA are at high risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's strategic focus includes expanding its presence in the US through partnerships and collaborations with major medical centers. The company also explores opportunities for global distribution through strategic partners outside the US. - Headquartered in Lund, Sweden - Primary market is the United States for pancreatic cancer detection - 1.8 million high-risk individuals in the USA for surveillance testing - Exploring global distribution through strategic partners ## Strategy Immunovia's strategic priorities include the commercialization of its PancreaSure test, securing strategic partnerships, and achieving reimbursement for its tests. The company focuses on targeted launches in the US market, leveraging relationships with top pancreatic cancer specialists to drive adoption. Immunovia is actively seeking a strategic partner to expand its commercial reach and accelerate market penetration. The company is also conducting additional clinical studies to secure reimbursement and enhance its competitive position. - **Commercialize PancreaSure test** (short-term) — To increase market penetration and revenue - **Secure strategic partnerships** (medium-term) — To expand commercial reach and reduce costs - **Achieve reimbursement** (medium-term) — To enhance test adoption and financial sustainability - Commercialize PancreaSure test in the US market - Secure strategic partnerships for expanded reach - Achieve reimbursement for tests to enhance market penetration - Conduct clinical studies to support reimbursement and adoption ## Risks Immunovia faces several operational and financial risks, including the development and validation of new tests, dependence on collaboration partners, and market acceptance challenges. The company is also exposed to currency risks due to its international operations, primarily related to USD and EUR fluctuations. Additionally, there are risks related to securing reimbursement and competition in the diagnostics industry. Liquidity risk is managed through careful cash flow planning and securing necessary funding. - **Development and validation of new tests** [high] — Critical for product success and market entry - **Market acceptance and reimbursement** [high] — Essential for revenue generation and growth - **Currency risks** [medium] — Exposure to USD and EUR affects financial results - Development and validation of new tests - Dependence on collaboration partners and suppliers - Market acceptance and reimbursement challenges - Currency risks related to USD and EUR fluctuations - Competition in the diagnostics industry - Liquidity risk and funding requirements ## Accounting Immunovia applies IFRS standards, with key accounting matters including revenue recognition and lease accounting. Revenue from the PancreaSure test is recognized upon delivery of test results, which impacts the timing of revenue recognition. The company also manages lease agreements for office and lab premises, affecting financial liabilities and cash flow. Changes in accounting standards are monitored to ensure compliance and accurate financial reporting. - **Revenue recognition** — high - **Lease accounting** — medium - Revenue recognition upon delivery of test results - Lease accounting for office and lab premises - Monitoring changes in accounting standards - Impact of revenue recognition timing on financial results --- *Last updated: 2026-08-11T04:04:53.347675+00:00*